Kaerus Bioscience has received US Food and Drug Administration’s (FDA) designations for KER-0193 to treat Fragile X syndrome ...

Kaerus Bioscience has received orphan drug and rare paediatric drug designations from the FDA for KER-0193, its lead ...

UK-based Kaerus Bioscience, a biopharma created by European investment firm Medicxi for the development of therapeutics for ...

QurAlis Corporation ("QurAlis"), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of ...

Local oil painter creates a permanent display of farm animals that passersby can stumble upon and enjoy in Cambridge.

"Not only do these two FDA designations affirm the therapeutic potential of KER-0193 in Fragile X syndrome, they also provide Kaerus with access to significant regulatory and financial incentives ...

FXS, the leading genetic form of intellectual disability and autism spectrum disorder, is caused by loss of the FMR1 encoded protein Fragile X Messenger Ribonucleoprotein (FMRP). It currently ...

When a Danforth man was born, doctors told his parents he would never ever talk. He recently spoke to a crowd.

QurAlis Corporation (“QurAlis”), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of ...

Fragile X syndrome is the leading inherited form of intellectual disability and the most common single genetic cause of autism. It is a genetic condition caused by a mutation of a single gene ...